Edwards Lifesciences (EW) vs Smith & Nephew SNATS (SNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Edwards Lifesciences (EW) has outperformed Smith & Nephew SNATS (SNN) over the past year, gaining 11.8% versus a loss of 24.7%. Over five years, EW leads with a -23.5% price change compared with -24.0% for SNN. Edwards Lifesciences is the larger company by market cap ($49.44 billion vs $11.25 billion), about 4.4 times the size.
On valuation, Smith & Nephew SNATS trades at a lower forward P/E (11.2x vs 25.4x for Edwards Lifesciences). Smith & Nephew SNATS pays a dividend yielding 1.48%, while Edwards Lifesciences does not currently pay one. Edwards Lifesciences converts more of its revenue into profit, with a net margin of 17.7% versus 10.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EW | SNN |
|---|---|---|
| Share price | $85.78 | $26.89 |
| Market cap | $49.44B | $11.25B |
| 1-day change | -0.81% | +0.07% |
| YTD return | +0.62% | -18.04% |
| 1-year return | +11.81% | -24.74% |
| 5-year return | -23.52% | -24.02% |
| P/E ratio (TTM) | 51.06 | 18.29 |
| Forward P/E | 25.40 | 11.16 |
| EPS (TTM) | $1.68 | $1.47 |
| Dividend yield | 0.00% | 1.48% |
| Annual dividend | $0.00 | $0.397 |
| Revenue (latest FY) | $6.07B | $6.16B |
| Revenue growth (YoY) | +11.55% | +6.09% |
| Net income (latest FY) | $1.07B | $625.00M |
| Gross margin | 78.01% | 68.01% |
| Operating margin | 20.84% | 12.88% |
| Net margin | 17.69% | 10.14% |
| 52-week high | $96.29 | $37.51 |
| 52-week low | $72.30 | $26.12 |
| Distance from 52-week high | -10.91% | -28.31% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +18.86% | +20.19% |
| Average volume | 3.82M | 1.66M |
| Shares outstanding | 576.40M | 418.52M |
| Employees | 16,000 | 17,000 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Edwards Lifesciences is about 4.4 times larger than Smith & Nephew SNATS by market value ($49.44B vs $11.25B).
- EW has outperformed SNN by 36.6 percentage points over the past year.
- Edwards Lifesciences trades at a higher earnings multiple (51.1x vs 18.3x trailing P/E).
- Smith & Nephew SNATS offers a meaningfully higher dividend yield (1.48% vs 0.00%).
- Edwards Lifesciences is more profitable, keeping 17.7 cents of every revenue dollar as net income versus 10.1 cents for Smith & Nephew SNATS.
- Edwards Lifesciences grew revenue faster in its latest fiscal year (+11.55% vs +6.09%).
About Edwards Lifesciences
EW stock →Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
Health Care · Industrial Specialties · 16,000 employees
About Smith & Nephew SNATS
SNN stock →Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Health Care · Industrial Specialties · 17,000 employees
EW vs SNN FAQ
Which is bigger, Edwards Lifesciences or Smith & Nephew SNATS?
Edwards Lifesciences (EW) is larger, with a market capitalization of $49.44B compared with $11.25B for Smith & Nephew SNATS (SNN).
Which stock has performed better over the past year, EW or SNN?
EW returned +11.81% over the past 12 months, compared with -24.74% for SNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, EW or SNN?
SNN has the lower trailing P/E at 18.3, versus 51.1 for EW. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Edwards Lifesciences or Smith & Nephew SNATS?
Smith & Nephew SNATS pays a dividend yielding 1.48%, while Edwards Lifesciences does not currently pay a regular dividend.
Are Edwards Lifesciences and Smith & Nephew SNATS in the same industry?
Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.